Svb Leerink Analysts Increase Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) – Analysts at Svb Leerink increased their FY2021 earnings per share estimates for Merck & Co., Inc. in a research note issued on Wednesday, November 20th. Svb Leerink analyst D. Graybosch now forecasts that the company will post earnings of $5.98 per share for the year, up from their prior estimate of $5.93. Svb Leerink has a “Outperform” rating and a $103.00 price objective on the stock. Svb Leerink also issued estimates for Merck & Co., Inc.’s FY2022 earnings at $6.22 EPS and FY2023 earnings at $6.52 EPS.

Several other research analysts also recently commented on the company. Bank of America assumed coverage on Merck & Co., Inc. in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price objective for the company. JPMorgan Chase & Co. set a $96.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, October 10th. Morgan Stanley increased their price objective on Merck & Co., Inc. from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Deutsche Bank reissued a “neutral” rating and issued a $104.00 price objective on shares of Merck & Co., Inc. in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and an average price target of $96.24.

Shares of MRK stock traded down $0.66 during trading hours on Thursday, hitting $84.61. 1,235,896 shares of the company’s stock were exchanged, compared to its average volume of 10,021,851. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. The firm has a market cap of $216.15 billion, a P/E ratio of 19.49, a P/E/G ratio of 1.84 and a beta of 0.54. The firm has a 50 day moving average of $84.10 and a two-hundred day moving average of $83.23. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. The business had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 EPS.

A number of large investors have recently modified their holdings of the business. Valmark Advisers Inc. grew its holdings in Merck & Co., Inc. by 1.9% in the 3rd quarter. Valmark Advisers Inc. now owns 8,788 shares of the company’s stock valued at $740,000 after buying an additional 161 shares in the last quarter. Financial Architects Inc grew its holdings in Merck & Co., Inc. by 1.1% in the 3rd quarter. Financial Architects Inc now owns 20,633 shares of the company’s stock valued at $1,737,000 after buying an additional 216 shares in the last quarter. Cetera Advisor Networks LLC grew its holdings in Merck & Co., Inc. by 0.7% in the 3rd quarter. Cetera Advisor Networks LLC now owns 124,747 shares of the company’s stock valued at $10,486,000 after buying an additional 815 shares in the last quarter. Trillium Asset Management LLC grew its holdings in Merck & Co., Inc. by 1.3% in the 3rd quarter. Trillium Asset Management LLC now owns 471,330 shares of the company’s stock valued at $39,677,000 after buying an additional 6,062 shares in the last quarter. Finally, Tiedemann Advisors LLC grew its holdings in Merck & Co., Inc. by 6.2% in the 3rd quarter. Tiedemann Advisors LLC now owns 26,940 shares of the company’s stock valued at $2,282,000 after buying an additional 1,569 shares in the last quarter. Institutional investors own 74.84% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Understanding the two types of arbitrage

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.